A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
Public ClinicalTrials.gov record NCT04417894. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients with atopic hand and foot dermatitis. The secondary objectives of the study are: * To assess the efficacy of dupilumab on various other domains (pruritus, pain, sleep loss, health related QoL, work life impairment) in patients with atopic hand and foot dermatitis * To evaluate the safety and tolerability of dupilumab administered to patients with atopic hand and foot dermatitis * To evaluate systemic exposure and immunogenicity of dupilumab in patients with atopic hand and foot dermatitis
Study identification
- NCT ID
- NCT04417894
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 133 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2021 (Actual)
- Primary completion
- Aug 31, 2022 (Actual)
- Completion
- Nov 23, 2022 (Actual)
- Last update posted
- Dec 22, 2023
2021 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Study Site | Birmingham | Alabama | 35209 | — |
| Regeneron Study Site | Redwood City | California | 94063 | — |
| Regeneron Study Site | Washington D.C. | District of Columbia | 20037 | — |
| Regeneron Study Site | Macon | Georgia | 31217 | — |
| Regeneron Study Site | Sandy Springs | Georgia | 30328 | — |
| Regeneron Study Site | Columbus | Indiana | 47201 | — |
| Regeneron Study Site | Rockville | Maryland | 20850 | — |
| Regeneron Study Site | Saint Joseph | Missouri | 64506 | — |
| Regeneron Study Site | St Louis | Missouri | 63104 | — |
| Regeneron Study Site | Kew Gardens | New York | 11415 | — |
| Regeneron Study Site | Mineola | New York | 11501 | — |
| Regeneron Study Site | Winston-Salem | North Carolina | 27157 | — |
| Regeneron Study Site | Portland | Oregon | 97239 | — |
| Regeneron Study Site | Houston | Texas | 77004 | — |
| Regeneron Study Site | Norfolk | Virginia | 23502 | — |
| Regeneron Study Site | Morgantown | West Virginia | 26505 | — |
| Regeneron Study Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04417894, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 22, 2023 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04417894 live on ClinicalTrials.gov.